Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Myriad Genetics, Inc. Banner

Myriad Genetics, Inc.

MYGN Stock Analysis

Page title

Section title

Breakdown
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Net Income
176.225M80.200M125.300M21.800M131.000M4.600M4.600M-223.700m-27.200m-112.000m
Depreciation & Amortization
13.819M25.000M26.700M48.300M54.400M73.000M73.000M71.400M62.800M52.700M
Change in Working Capital
-59.973m-40.700m-65.400m-36.600m-21.600m-37.100m-37.100m30.200M120.400M-101.500m
Operating Cash Flow
190.213M140.500M166.300M106.200M115.900M83.700M83.700M-26.900m18.200M-106.300m
Capital Expenditure
-14.271m-23.900m-5.000m-6.100m-8.400m-8.600m-8.600m-13.200m-18.000m-45.300m
Free Cash Flow
175.942M116.600M161.300M100.100M107.500M75.100M75.100M-40.100m200.000K-151.600m
Debt Repayment
0.0000.0000.000-305.000m-143.000m-115.000m-115.000m-8.600m-226.400m0.000
Dividends Paid
0.0000.0000.000-403.000m0.000-340.000m-340.000m0.0000.0000.000
Common Stock Issued
0.00030.000M0.0006.000M36.900M8.700M8.700M0.00091.800M6.300M
Common Stock Repurchased
-287.703m-210.700m-162.600m-31.600m0.000-50.000m-50.000m-3.900m0.0000.000
Net Change in Cash
-39.252m-700.000k4.400M33.900M8.500M-17.700m-17.700m70.500M141.400M-192.400m